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Plasma total homocysteine and cysteine in relation to glomeru- An elevated plasma concentration of the amino acid
lar filtration rate in diabetes mellitus. homocysteine is associated with precocious atherosclero-
Background. The plasma concentrations of total homocys- sis in patients with inherited homocystinuria, irrespec-
teine (tHcy) and total cysteine (tCys) are determined by intra-
tively of the site of the responsible enzyme deletion [1, 2].cellular metabolism and by renal plasma clearance, and we
Experimental studies have shown that high concentra-hypothesized that glomerular filtration is a major determinant
of plasma tHcy and tCys. We studied the relationships between tions of homocysteine may cause vascular damage [3],
the glomerular filtration rate (GFR) and plasma tHcy and tCys and epidemiological studies published during the last 10
in populations of diabetic patients with particularly wide ranges years show that an elevated total homocysteine (tHcy)
of GFR.
concentration in plasma is associated with symptoms ofMethods. We measured GFR, urine albumin excretion rate
cardiovascular disease (CVD) [4–19]. Thus, clinical, ex-(UAER), plasma tHcy, tCys, methionine, vitamin B12, folate,
perimental, and epidemiological evidence all suggest aC-peptide, and routine parameters in 50 insulin-dependent dia-
betes mellitus (IDDM) and 30 non–insulin-dependent diabetes link between atherosclerosis and plasma tHcy. Diabetic
mellitus (NIDDM) patients. All patients underwent intensive patients have a twofold to sixfold higher prevalence of
insulin treatment and had a serum creatinine concentration atherosclerosis than nondiabetic persons [20–22], but thebelow 115 mmol/liter.
relationship between plasma tHcy and this excess of ath-Results. Mean plasma tHcy in diabetic patients (0.1 mmol/
erosclerosis is unknown. In spite of their higher preva-liter) was lower than in normal persons (11.1 mmol/liter, P 5
0.0014). Mean plasma tCys in diabetic patients (266.1 mmol/ lence of CVD compared with nondiabetic persons, the
liter) was also lower than in normal persons (281.9 mmol/liter, mean plasma tHcy concentration is normal or low in
P 5 0.0005). Seventy-three percent of the diabetic patients had insulin-dependent diabetes mellitus (IDDM) and non–
relative hyperfiltration. Plasma tHcy and tCys were closely and
insulin-dependent diabetes mellitus (NIDDM) patientsindependently associated with GFR, serum folate, and serum
[23–26]. The cause of this low plasma tHcy relative toB12. However, plasma tHcy was not independently associated
the high prevalence of CVD in populations of diabeticwith any of the 22 other variables tested, including age, serum
creatinine concentration, UAER, total daily insulin dose, and patients is not known.
glycemic control. The plasma concentration of tHcy is determined by
Conclusions. Glomerular filtration rate is an independent intracellular metabolism of homocysteine within the acti-determinant of plasma tHcy and tCys concentrations, and GFR
vated methyl cycle [27], by trans-sulfuration to cysteineis rate limiting for renal clearance of both homocysteine and
[28], and by renal clearance [29]. Abnormally low levels ofcysteine in diabetic patients without overt nephropathy. De-
clining GFR explains the age-related increase in plasma tHcy, plasma tHcy might be an effect of abnormal homocysteine
and hyperfiltration explains the lower than normal mean metabolism in the diabetic organism. However, the plasma
plasma tHcy and tCys concentrations in populations of diabetic concentration of tHcy in diabetic patients might also be
patients.
an effect of abnormal renal clearance of homocysteine.
In normal kidneys, plasma amino acids are first filtered
in glomeruli, then reabsorbed in tubuli, and finally de-Key words: NIDDM, IDDM, glomerular filtration rate, clearance, age,
hyperfiltration, folate, methyl cycle. graded in renal parenchyma. Bostom et al showed that
degradation in renal tissue following tubular reabsorptionReceived for publication May 28, 1998
of homocysteine is a major fraction of total plasma tHcyand in revised form October 1, 1998
Accepted for publication October 1, 1998 clearance in the rat [30]. The authors suggested that the
reduced metabolic capacity of kidney tissue might be 1999 by the International Society of Nephrology
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rate limiting for renal tHcy clearance and might cause liter, limiting the study to 80 patients with clinically nor-
mal renal function (Table 1).the elevation of plasma tHcy seen in human end-stage
Plasma samples from 160 healthy men between therenal disease [31, 32]. However, although a reduced met-
ages of 41 and 68 (median 54) and 169 healthy womenabolic capacity of kidney tissue may explain the elevated
between the ages of 41 and 69 (median 54) defined theplasma tHcy concentrations in patients with end-stage
normal ranges for tHcy and tCys.nephropathy, reduced renal metabolic capacity is un-
likely to explain the decreased or normal mean plasma Protocol
tHcy concentrations of diabetic patients.
The following laboratory determinations were madeThe glomerular filtration rate (GFR) of diabetic pa-
at each visit to the clinic: fasting blood glucose, HbA1c,tients in unselected populations covers a wide range from
serum total cholesterol, high-density lipoprotein choles-
diabetic hyperfiltration to the hypofiltration of diabetic
terol, triglycerides, and creatinine, timed overnight uri-
nephropathy, and the mean GFR of each population nary albumin excretion rate (UAER), supine blood pres-
depends on the degree and prevalence of these two con- sure, and body weight. Blood samples were drawn in the
ditions. If the GFR were rate limiting for plasma tHcy morning before meals and before insulin administration.
clearance, then prevalent diabetic hyperfiltration would Results were calculated as the mean of four different
be expected to cause reduced mean tHcy concentrations. measurements within the last year of the observation
Furthermore, plasma tHcy then might be correlated to period. All other tests were done once during the year.
GFR independently of age, homocysteine metabolism,
Laboratory determinationsand glycemic control.
We hypothesized that GFR is rate limiting for plasma Plasma tHcy and total cysteine (tCys) were measured
in one assay using an automated, high-performance liquidtHcy clearance in persons without nephropathy, and we
chromatography method as previously described [10, 33].characterized the association between plasma tHcy and
The intra-assay coefficient of variation is less than 3%.GFR in populations of IDDM and NIDDM patients.
The normal ranges (mean 6 2 sd) were 6.1 to 19.9 mmol/The patients were under intensive glycemic control. They
liter for tHcy and 209.8 to 342.7 mmol/liter for tCys.had a wide range of GFR and had moderate microalbum-
Plasma C-peptide was measured by a modification ofinuria. Patients with serum creatinine above normal were
the radioimmunoassay described by Heding [34]. Sensi-excluded from the study.
tivity of the assay was 0.02 nmol/liter. Intra-assay coeffi-
cient of variation was 5.8%, and interassay coefficient
of variation was 8.1%. The normal range was 0.24 toMETHODS
0.64 nmol/liter.
Patients The following laboratory analyses were routine assays
All patients attended the same diabetes referral clinic. at the central clinical laboratory of the hospital, which
They had either IDDM (defined by a fasting serum C- participates in the Murex Quality Assessment Programs
peptide below 0.24 nmol/liter) or NIDDM with second- (Murex Biotech Ltd., Dartford, UK).
HbA1c was assessed by high-performance liquid chro-ary failure (defined by a fasting serum C-peptide equal
matography as described by Jeppsson et al [35]. Theto or above 0.24 nmol/liter and insulin requirements).
upper normal limit for the assay was 5.2%.Inclusion criteria were the need for insulin treatment
Serum vitamin B12 and folate were assayed simultane-and a willingness to undergo intensive insulin treatment
ously in a radioimmunoassay as described by Chen etintended to maintain HbA1c below 6.0% for a minimum
al [36]. The normal range for serum vitamin B12 was 125of two years.
to 700 pmol/liter, and for serum folate, it was 5 to 40All patients visited the diabetes clinic at least four
nmol/liter.times yearly. The insulin treatment of all patients was
Urinary albumin concentration was analyzed by anat least three daily injections of fast-acting insulin at
automated nephelometric enzyme-linked immunosor-
mealtime and two daily injections of intermediate-acting bent assay (Behringwerke AG, Marburg, Germany),
insulin in the morning and late afternoon throughout which is described by Tuengler et al [37]. The UAER
the study period. was calculated from an overnight timed urine collection
Two hundred and ten patients were referred for the done by the patient following written and oral instruc-
control of insulin treatment during the two-year inclusion tions. Normal range was 4 to 15 mg/min.
period, and 136 of these fulfilled the inclusion criteria. The GFR was determined after a single 51CR-EDTA
One hundred and nine patients completed the study. injection as the clearance over a period of four hours
Twenty-nine of the 109 patients were excluded because and expressed as milliliters per minute per square meter
of body surface area (ml/min/m2). The normal range forof a serum creatinine concentration above 115 mmol/
Wollesen et al: Homocysteine and GFR in diabetes mellitus1030
Table 1. Clinical characteristics of diabetic patients with serum creatinine below 115 mmol/liter
Variables Mean 95% Confidence interval Minimum Maximum
Plasma total homocysteine lmol /liter 10.1 9.5–10.7 5.4 21.0
Plasma total methionine lmol /liter 24.5 22.8–26.2 10.3 47.3
Plasma total cysteine lmol /liter 266 257–275 193 380
Serum folate nmol /liter 20 18–22 7 55
Serum vitamin B12 pmol /liter 334 295–372 191 1361
Glomerular filtration rate ml/min /1.73 m2 105 99–111 47 165
Urinary albumin excretion rate lg/min 33 19–46 4 310
Serum creatinine lmol /liter 90 87–93 59 113
Systolic blood pressure mm Hg 144 140–148 112 188
Diastolic blood pressure mm Hg 82 80–84 58 100
Age years 51 47–55 23 85
Duration of diabetes years 17 14–20 2 64
HbA1c % 6.3 6.0–6.5 4.4 10.2
20-year-old men and women is 85 to 135 ml/min/1.73 m2, per day, daily insulin dose, fasting blood sugar, HbA1c,
serum C-peptide, total cholesterol, high-density lipopro-and for 80-year-old men and women, it is 45 to 95 ml/
min/1.73 m2 [38]. tein cholesterol, triglyceride, and uric acid, plasma fi-
brinogen, tHcy, and tCys, serum vitamin B12 and folate,The sagittal abdominal diameter was measured on the
recumbent patient as the perpendicular distance be- UAER, GFR, serum creatinine, electrocardiogram-left
ventricular hypertrophy, systolic blood pressure, and dia-tween the plane of support and the highest point of the
abdomen. A specially constructed gallows was used for stolic blood pressure.
all measurements.
Skinfold thickness refers to the sum of the triceps,
RESULTS
subscapular, and suprailliac skinfolds measured ac-
Clinical characteristicscording to Reinken et al [39]. The skinfold thickness
was measured by one observer using a Holtain caliper Clinical characteristics of the 50 IDDM patients and
30 NIDDM patients in the study are listed in Table 1.(Holtain Ltd., Crymych, UK).
Left ventricular hypertrophy was estimated electrocar- The age range for IDDM patients was 22 to 79 years
[mean 47, 95% confidence interval (CI), 42 to 52 years]diographically as the sum of amplitudes of S in lead V1
and of R in lead V5. and for NIDDM patients, it was 23 to 85 years (mean
58, 95% CI, 53 to 63 years, P 5 0.0029). However, the
Data analysis two types of diabetic patients were not different with
respect to mean HbA1c (P 5 0.6450) or total daily insulinNormality of distribution was tested by the Shapiro
and Wilks W statistic. For variables with normal distribu- dose (P 5 0.3899).
Homocysteine. The mean tHcy plasma concentrationtions, the results were calculated as means with 95%
confidence limits. For nonnormally distributed variables, in all diabetic patients was 10.1 mmol/liter (95% CI, 9.5
to 10.7 mmol/liter; Table 1), which was lower than theresults were calculated as medians with interquartile
ranges. All t-tests were two tailed. A P value of less than mean plasma tHcy concentration of 329 normal control
persons, which was 11.1 (95% CI, 10.6 to 11.6 mmol/liter,0.05 was defined as significant. A one-way analysis of
covariance was used to adjust group means of plasma P 5 0.0014). The mean plasma tHcy concentration in
IDDM patients was 9.8 (95% CI, 9.0 to 10.6 mmol/liter),tHcy and tCys for covariates in stratification for intervals
of GFR. A two-way analysis of variance was applied to and in NIDDM patients, it was 10.6 mmol/liter (95% CI,
9.6 to 11.5 mmol/liter, P 5 0.2189). One patient (IDDM)decide the additive effect (interaction) of two variables
on plasma tHcy. had a plasma tHcy (23 mmol/liter) above the 95th percen-
tile (17.0 mmol/liter) of the 329 normal control persons.Simple associations between variables were calculated
as the Pearson coefficient of correlation (r). Two explor- The mean tCys plasma concentration of all diabetic
patients was 266 mmol/liter (95% CI, 257 to 275 mmol/ative multiple-regression models, stepwise regression,
and all possible subsets regression were used to identify liter; Table 1), and in 329 normal control persons, it
was 282 mmol/liter (95% CI, 278 to 286 mmol/liter, P 5the combination of variables with the best predictive
value [40]. The following variables or transformations 0.0005). The mean plasma tCys concentration in IDDM
patients was 261 mmol/liter (95% CI, 250 to 272 mmol/of these were tested both in simple-regression analyses
and in the multiple-regression models: age, duration of liter), and in NIDDM patients, it was 275 mmol/liter
(95% CI, 260 to 290 mmol/liter, P 5 0.1161).diabetes, body weight, abdominal sagittal diameter, sum
of three skinfold thicknesses, number of cigarettes smoked The mean methionine plasma concentration in IDDM
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patients was 24.4 mmol/liter (95% CI, 22.1 to 26.8 mmol/
liter), and in NIDDM patients, it was 24.6 mmol/liter
(95% CI, 22.1 to 27.1 mmol/liter, P 5 0.9069).
The mean folate serum concentration in IDDM pa-
tients was 21 (95% CI, 19 to 24 nmol/liter), and in
NIDDM patients, it was 18 nmol/liter (95% CI, 15 to
20, P 5 0.0963). The mean vitamin B12 serum concentra-
tion was 352 (95% CI, 296 to 409 pmol/liter), and in
NIDDM patients, it was 303 pmol/liter (95% CI, 110 to
558 pmol/liter, P 5 0.2185). All patients had folate and
serum vitamin B12 concentrations above the lower nor-
mal limits.
Renal function. All patients had clinically normal re-
nal function, defined as a serum creatinine concentration
below 115 mmol/liter and a UAER below 310 mg/min.
The GFR was above 135 ml/min/1.73 m2 (absolute
hyperfiltration) in four IDDM patients and in four
Fig. 1. Means and standard errors of the means for plasma total homo-NIDDM patients. Thirty-five IDDM patients (70%) and cysteine (tHcy) concentration stratified by equal intervals of the glomer-
23 NIDDM patients (77%) had a GFR that was more ular filtration rate (GFR) in 80 diabetic patients without overt nephropa-
thy. The mean plasma tHcy concentrations have been adjusted forthan 100% of the mean value for nondiabetic persons
serum folate and vitamin B12. The P value for equality of the adjustedof the same age and sex (relative hyperfiltration). The means , 0.0001. All differences between group means were significant
mean GFR for IDDM patients was 106 (95% CI, 100 to except for the difference between the two lowest means of tHcy. The
number of patients in the four intervals was 13, 27, 32, and 8, respec-111), and for NIDDM patients, it was 103 ml/min/1.73 m2
tively.(95% CI, 94 to 113 ml/min/1.73 m2, P 5 0.6232).
In the 58 diabetic patients who had a higher GFR than
the normal mean value for their age and sex, the mean
plasma tHcy concentration was 9.4 mmol/liter (95% CI, was 9.26 mmol/liter (95% CI, 8.61 to 9.91 mmol/liter, P 5
8.8 to 10.0 mmol/liter). In the 22 patients with a lower 0.0007).
GFR, the mean plasma tHcy concentration was 12.0 The GFR was also inversely related with age (partial
mmol/liter (95% CI, 10.7 to 13.3 mmol/liter, P , 0.0001). r 5 20.4977, P 5 2.626), with serum creatinine (partial
The UAER distribution was significantly skewed in r 5 20.5017, P 5 2.126), and with plasma tCys (par-
both IDDM and NIDDM patients with P values for tial r 5 20.5298, P 5 4.327). However, GFR was not
Wilks statistic of less than 0.0001 in both types of diabe- related with serum folate (partial r 5 20.0439, P 5
tes. Seventeen IDDM patients (34%) and nine NIDDM
0.6987) or with plasma methionine (partial r 5 0.0655,
patients (30%) had a UAER between 15 and 310 mg/
P 5 0.5638). In the 58 patients with relative hyperfiltra-min (microproteinuria). Median UAER was 8 mg/min
tion, GFR remained inversely related to age (partial r 5in IDDM patients (range 4.3 to 220) and 9 mg/min in
20.5297, P 5 1.925), although other factors than ageNIDDM patients (range 4.4 to 310, Mann–Whitney P
contributed to GFR in this group of hyperfiltrating dia-value 5 0.8180).
betic patients.Fifty-four patients with a UAER below or equal to
Age was closely related with plasma tCys (partial r 515 mg/min had a mean plasma tHcy concentration of 9.7
0.6116, P 5 1.729), but not with serum folate (partial r 5mmol/liter (95% CI, 9.0 to 10.4). In the 14 patients with
0.1615, P 5 0.7099) or with plasma methionine (partialUAER between 15 and 51 mg/min, the mean plasma tHcy
r 5 0.1615, P 5 0.1524).concentration was 9.8 mmol/liter (95% CI, 8.6 to 11.0).
Multivariate relationshipsBivariate relationships
A one-way analysis of variance between plasma tHcyThe plasma tHcy concentration was strongly corre-
and GFR with serum folate and vitamin B12 as covariateslated with GFR, as shown in Figures 1 and 2 and Table 2.
is shown in Figure 1 (P , 0.0001). The mean plasma tCysMean plasma tHcy in 39 patients below age 50 was
for the same four intervals of GFR was also significantly9.12 mmol/liter (95% CI, 8.44 to 9.81 mmol/liter) and in
different, except for the two groups with the highest41 patients above age 50, it was 11.0 mmol/liter (95%
GFR (P , 0.0001). A two-way analysis of variance forCI, 10.1 to 11.9 mmol/liter, P 5 0.0016). The mean plasma
plasma tHcy with respect to age and GFR is presentedtHcy in 32 patients with GFR below 100 ml/min/1.73 m2
in Table 3. The best possible subset of predictor variableswas 11.3 mmol/liter (95% CI, 10.3 to 12.4 mmol/liter) and
in 48 patients with GFR above 100 ml/min/1.73 m2, it selected from a pool of 25 relevant variables for the
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Fig. 2. Scatterplot and simple regression analy-
sis of plasma homocysteine (tHcy) concentra-
tions and glomerular filtration rates in 80 dia-
betic patients without overt nephropathy (r 5
0.4351; P , 0.0001).
Table 2. Stratification of clinical characteristics by glomerular filtration rate (GFR) in eighty diabetic patients
with serum creatinine below 115 mmol /liter
GFR ml/min /1.73 m2
47 to 76 77 to 106 107 to 136 136 to 165
Variables N 5 13 N 5 27 N 5 32 N 5 8
Plasma total homocysteine lmol /liter 12.1 (10.7–13.5) 10.4 (9.3–11.7) 9.4 (8.6–10.3) 8.0 (6.8–9.3)
Plasma total methionine lmol /liter 23.5 (19.6–27.4) 23.4 (21.0–25.8) 26.3 (23.0–29.6) 22.5 (16.9–28.1)
Plasma total cysteine lmol /liter 304 (284–324) 280 (265–295) 245 (234–256) 243 (230–255)
Serum folate nmol /liter 21 (13–29) 20 (17–24) 19 (16–21) 22 (19–26)
Serum vitamin B12 pmol /liter 400 (211–588) 331 (266–396) 309 (268–351) 332 (259–404)
Urinary albumin excretion rate lg/min 81 (17–145) 35 (12–59) 15 (7–24) 14 (5–24)
Serum creatinine lmol /liter 99 (93–106) 93 (87–98) 87 (83–91) 79 (71–87)
Systolic blood pressure mm Hg 150 (143–158) 150 (142–157) 137 (130–143) 145 (129–161)
Diastolic blood pressure mm Hg 80 (74–85) 85 (82–89) 79 (77–82) 84 (76–92)
Age years 69 (63–74) 54 (48–60) 44 (39–49) 43 (35–51)
Duration of diabetes years 24 (13–34) 20 (15–25) 13 (10–17) 13 (7–19)
HbA1c % 6.2 (5.7–6.7) 6.5 (5.9–7.0) 6.1 (5.8–6.5) 6.4 (5.7–7.1)
Numbers are means and 95% confidence limits.
plasma tHcy concentration of 80 diabetic patients is DISCUSSION
shown in Table 4. Serum folate and serum vitamin B12 We have shown that GFR is a strong determinant
contributed to the model independently of each other of the plasma tHcy and tCys concentrations, and that
with tolerance values of 0.8416 and 0.8111, respectively. diabetic patients with relative hyperfiltration have lower
Most of the predictive effects of age and serum creatinine than normal plasma tHcy and tCys. GFR determines the
were contributed to the model through collinearity with plasma tHcy and tCys concentrations independently of
plasma tCys and GFR. With plasma tCys and GFR in age, serum vitamins, serum creatinine, and UAER. No
the model, no further prediction was contributed either combinations of these variables fully explain the rela-
by age or serum creatinine alone or in combination. tionships between GFR and plasma tHcy and tCys.
Therefore, GFR contributed more to prediction of varia- The GFR was closely and independently associated
tions in plasma tHcy than contributions by age and serum with plasma tHcy and tCys. The associations were found
creatinine, and GFR entered the model independently over the entire range of GFR, showing that a dose–
of plasma tCys, serum folate, and serum vitamin B12. The response relationship exists between GFR and plasma
model was underspecified, with an adjusted R2 of 0.4444, tHcy and tCys. Our findings agree with observations of
and other contributing variables than those tested in this plasma tHcy and tCys in nondiabetic patients published
by Arnadottir et al [29]. Homocysteine is ultrafiltratedstudy remain unidentified.
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Table 4. Multiple regression analysis with plasma totalTable 3. Two-way analysis of variance of plasma total homocysteine
(mmol/liter) for two levels of GFR (ml/min/1.73 m2) homocysteine as dependent variable in eighty diabetic
patients with serum creatinine below 115 mmol/literand two levels of age
GFR , 100 GFR . 100 Independent variables Partial r P value
Age
years N Mean 95% CI N Mean 95% CI In model
Plasma total cysteine 0.4843 0.000005
,51 7 10.7 9.0–12.4 33 8.8 8.1–9.6 Serum folate 20.4577 0.00002
$51 25 11.5 10.2–12.9 15 10.2 8.8–11.5 Serum B12 vitamin 20.2519 0.0261
Glomerular filtration rate 20.2495 0.0286P value for GFR effect is 0.0183; P value for age effect, 0.0920; and P value
for interaction effect, 0.6463. Not in model
Serum creatinine 0.0954 0.4125
Age 20.0099 0.9320
Multiple R2 5 0.4686
in glomeruli, almost completely absorbed in tubuli, and
degraded in kidney tissue by transmethylation and trans-
sulfuration in the activated methyl cycle [27]. van Gulde-
cysteine trans-sulfuration and the rate of glomerular fil-ner et al recently found that humans with normal kidneys
tration were the two major, independent determinantsreturn as much homocysteine to the circulation as is
of the plasma concentration of tHcy.ultrafiltrated in glomeruli [41]. Bostom et al have shown
Aging reduces GFR, and in our study, the associationthat metabolism in kidney tissue accounts for a major
of plasma tHcy with age was entirely caused by this effectfraction of total renal clearance of plasma homocysteine
of age on GFR, because adjustment for GFR eliminated[30], and suggested that loss of capacity for homocysteine
the association between tHcy and age. Thus, decliningdegradation might explain the increase in plasma tHcy
GFR may explain the age-related increase in plasmaseen in end-stage renal disease. With this background,
tHcy found in both diabetic patients and nondiabeticwe interpret the close relationship between GFR and
persons.the plasma concentration of tHcy in our patients to show
The mean plasma tHcy and tCys concentrations inthat normal kidney tissue compensates for changes in
diabetic patients were lower than in our population ofultrafiltration by regulating the degradation of homocys-
normal control persons with the same age range andteine, thus keeping the return of homocysteine to the
sex ratio. Despite the exclusion of patients with serumcirculation constant. When GFR and ultrafiltration and
creatinine concentrations above normal, 33% of our dia-tubular absorption of homocysteine are reduced, trans-
betic patients, nevertheless, had microalbuminuria. How-methylation and trans-sulfuration are also reduced, and
ever, microalbuminuria had no effect on the relationshipan unchanged amount of homocysteine is returned to
between GFR and plasma tHcy and tCys, a finding thatthe circulation. When GFR is increased, transmethyla-
agrees with that of Agardh et al in IDDM patients [23].tion and trans-sulfuration are increased to keep the re-
Diabetic hyperfiltration was found in 10% of our pa-turn of homocysteine to the circulation constant. These
tients, and 72% had a GFR above the normal mean forcompensatory mechanisms in the autoregulated, acti-
their age and sex. Robillon et al also found reducedvated methyl cycle explain the association between GFR
plasma tHcy in IDDM patients without overt nephropa-and plasma tHcy and tCys in patients with normal renal
thy [24], whereas Araki et al [25] and Munshi et al [26]tissue function. The associations of plasma tHcy and tCys
found normal plasma tHcy, and Hofman et al [43] foundwith GFR show that GFR is rate limiting for kidney
elevated tHcy in studies of diabetic populations that in-clearance of plasma homocysteine and cysteine in pa-
cluded patients with nephropathy. In populations of dia-tients with intact renal parenchyma. Thus, age-depen-
betic patients, including patients with nephropathy, ei-dent reduction of GFR causes increased plasma tHcy,
ther renal tissue damage or reduced GFR or both mayand diabetic hyperfiltration causes decreased plasma
cause the mean plasma tHcy to rise to normal or abovetHcy concentration.
normal concentrations, depending on the prevalence ofSerum folate was negatively associated with plasma
nephropathy. We consider the low mean plasma tHcy andtHcy. This association is well known in nondiabetic per-
tCys concentrations of diabetic patients without ne-sons [17, 32, 42] and reflects homocysteine remethylation
phropathy to be an effect of their relative hyperfiltration.to methionine in the activated methyl cycle [27]. Plasma
The strong influence of renal clearance on the plasmatCys was positively related to both serum folate and
concentrations of tHcy and tCys implies that associationsplasma tHcy, a finding that fully supports the concept
between plasma tHcy and tCys and other age-relatedof coordinate remethylation and trans-sulfuration in the
variables must be adjusted for renal function. Serum creat-metabolism of homocysteine, first proposed by Selhub
inine has often been used to adjust for this effect of renaland Miller [28]. The strong, positive correlation between
function on the relationship between plasma tHcy andtHcy and tCys was independent of GFR, age, serum
folate, and plasma methionine. Thus, the rate of homo- age-related CVD [44, 45]. However, the close association
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